Brinker A, et al. - In this study, investigators evaluated the FDA Adverse Event Reporting System (FAERS) and the PubMed databases from September 25, 2009, to November 20, 2017, to assess and identify post-marketing cases of noninfectious pneumonia correlated with ustekinumab use. They identified 12 cases: 7 interstitial pneumonia, 3 eosinophilic pneumonia, 1 organizing pneumonia, and 1 hypersensitivity pneumonitis diagnoses. They noted all the cases as a serious outcome, including 7 hospitalizations and 1 respiratory failure requiring mechanical ventilation. Findings suggested a correlation between noninfectious pneumonia and use of ustekinumab given that pulmonary symptoms were evident after 1-3 doses of ustekinumab in 75% of cases.